Skip to main content
Erschienen in:

28.01.2019 | Oropharynxkarzinom | Leitthema

Behandlungsstrategien beim Oropharynxkarzinom

verfasst von: Prof. Dr. Andreas Dietz

Erschienen in: Die Onkologie | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Hintergrund

Das Oropharynxkarzinom (OPSCC) stellt aufgrund seiner weltweiten Inzidenzzunahme und der Assoziation mit dem humanen Papillomavirus HPV-16, aber auch chronischem Tabak‑/Alkoholkonsum eine genetisch heterogene Tumorgruppe mit hoher prognostischer Diversität dar.

Ziel

Die Übersichtsarbeit versucht, die aktuelle Sicht der Therapie und Prävention des OPSCC in Hinblick auf die Assoziation mit HPV16 darzustellen.

Material und Methoden

Die Übersicht erfolgt auf der Basis der aktuellen relevanten Literatur sowie der derzeit laufenden Studien.

Ergebnisse und Diskussion

Das OPSCC stellt sich als sehr komplexe, genetisch heterogene und daher detailliert anzusehende Gruppe von Kopf-Hals-Tumoren dar. Die derzeit widersprüchliche Studienlage, die auf dem Boden retrospektiver Daten aktuelle TNM-Klassifikation („8th Edition“) und die abzuwartenden prospektiven Daten zur Therapiedeintensivierung ermahnen aktuell eher zu einer konservativen Therapiebetrachtung. Durch die aktuellen Impfempfehlungen ist jetzt auch die HPV-Impfung für Jungen analog zu den Mädchen in Deutschland zugelassen.
Literatur
1.
Zurück zum Zitat Dietz A, Pirlich M, Wiegand S (2018) Current Status of therapy and prophylaxis of oropharyngeal carcinoma. Laryngorhinootologie 97(2):123–137PubMedCrossRef Dietz A, Pirlich M, Wiegand S (2018) Current Status of therapy and prophylaxis of oropharyngeal carcinoma. Laryngorhinootologie 97(2):123–137PubMedCrossRef
2.
Zurück zum Zitat Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990. Springer, Berlin, Heidelberg, New York (Fortschreibung im Internet: www.krebsatlas.de) Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990. Springer, Berlin, Heidelberg, New York (Fortschreibung im Internet: www.​krebsatlas.​de)
3.
Zurück zum Zitat Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58(1):5–13PubMed Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58(1):5–13PubMed
4.
Zurück zum Zitat Wichmann G (2017) Variation of HPV subtypes with focus on HPV-infection and cancer in the head and neck region. Recent Results Cancer Res 206:113–122PubMedCrossRef Wichmann G (2017) Variation of HPV subtypes with focus on HPV-infection and cancer in the head and neck region. Recent Results Cancer Res 206:113–122PubMedCrossRef
5.
Zurück zum Zitat Wagner S, Würdemann N, Hübbers C, Reuschenbach M, Prigge ES, Wichmann G, Hess J, Dietz A, Dürst M, Tinhofer I, von Knebel-Döberitz M, Wittekindt C, Klussmann JP (2015) HPV-associated head and neck cancer : mutational signature and genomic aberrations. HNO 63(11):758–767PubMedCrossRef Wagner S, Würdemann N, Hübbers C, Reuschenbach M, Prigge ES, Wichmann G, Hess J, Dietz A, Dürst M, Tinhofer I, von Knebel-Döberitz M, Wittekindt C, Klussmann JP (2015) HPV-associated head and neck cancer : mutational signature and genomic aberrations. HNO 63(11):758–767PubMedCrossRef
6.
Zurück zum Zitat Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U, Holzinger D, Pawlita M, Hess J, Engel C, Hasenclever D, Scholz M, Ahnert P, Kirsten H, Hemprich A, Wittekind C, Herbarth O, Horn F, Dietz A, Loeffler M, Leipzig Head and Neck Group (LHNG) (2015) The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 137(12):2846–2857PubMedCrossRef Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U, Holzinger D, Pawlita M, Hess J, Engel C, Hasenclever D, Scholz M, Ahnert P, Kirsten H, Hemprich A, Wittekind C, Herbarth O, Horn F, Dietz A, Loeffler M, Leipzig Head and Neck Group (LHNG) (2015) The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 137(12):2846–2857PubMedCrossRef
7.
Zurück zum Zitat 8th Edition of the UICC TNM Classification of Malignant Tumours, 1 January 2017. 8th Edition of the UICC TNM Classification of Malignant Tumours, 1 January 2017.
8.
Zurück zum Zitat Boscolo-Rizzo P, Dietz A (2017) The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de-escalate treatment regimens in p16-positive oropharyngeal cancer patients? Int J Cancer 141(7):1490–1491PubMedCrossRef Boscolo-Rizzo P, Dietz A (2017) The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de-escalate treatment regimens in p16-positive oropharyngeal cancer patients? Int J Cancer 141(7):1490–1491PubMedCrossRef
9.
Zurück zum Zitat Golusinski W, Leemans R, Dietz A (2017) HPV infection on head and neck cancer. Springer, Berlin Heidelberg. ISBN 978-3319435800CrossRef Golusinski W, Leemans R, Dietz A (2017) HPV infection on head and neck cancer. Springer, Berlin Heidelberg. ISBN 978-3319435800CrossRef
10.
Zurück zum Zitat Robinson M, Schache A, Sloan P, Thavaraj S (2012) HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol 6:83–90PubMedCentralCrossRef Robinson M, Schache A, Sloan P, Thavaraj S (2012) HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol 6:83–90PubMedCentralCrossRef
11.
Zurück zum Zitat Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121:2465–2472PubMedCrossRef Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121:2465–2472PubMedCrossRef
12.
Zurück zum Zitat Lewis JS Jr. (2012) p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 6:75–82PubMedCentralCrossRef Lewis JS Jr. (2012) p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 6:75–82PubMedCentralCrossRef
13.
Zurück zum Zitat Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O’Sullivan B, Kenny LM, McArthur GA (2010) Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142–4148PubMedPubMedCentralCrossRef Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O’Sullivan B, Kenny LM, McArthur GA (2010) Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142–4148PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Wasylyk B, Abecassis J, Jung AC (2013) Identification of clinically relevant HPV-related HNSCC: in p16 should we trust? Oral Oncol 49:e33–e37PubMedCrossRef Wasylyk B, Abecassis J, Jung AC (2013) Identification of clinically relevant HPV-related HNSCC: in p16 should we trust? Oral Oncol 49:e33–e37PubMedCrossRef
15.
Zurück zum Zitat Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Ullmann CD (2009) Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. Head Neck 31:1393–1422PubMedCrossRef Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D’Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Ullmann CD (2009) Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. Head Neck 31:1393–1422PubMedCrossRef
16.
Zurück zum Zitat Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35PubMedPubMedCentralCrossRef Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Brotherston IP, Le T, Leung M, Kiss A, Ringash J, Balogh J, Lee J, Wright JR (2013) Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck 35(2):151–159PubMedCrossRef Brotherston IP, Le T, Leung M, Kiss A, Ringash J, Balogh J, Lee J, Wright JR (2013) Patient preferences for oropharyngeal cancer treatment de-escalation. Head Neck 35(2):151–159PubMedCrossRef
18.
Zurück zum Zitat Mehanna H, Kong A, Hartley A, Mistry P, Dalby M, Fulton-Lieuw T, Robinson M, Gray A, Foran B, Sen M, O’Toole L, Dyker K, Al Booz H, Moleron R, Brennan S, Aynsley E, Chan A, Srinivasan D, Buter J, Dunn J (2018) Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. Ann Oncol 29(suppl_8). https://doi.org/10.1093/annonc/mdy424.046 CrossRef Mehanna H, Kong A, Hartley A, Mistry P, Dalby M, Fulton-Lieuw T, Robinson M, Gray A, Foran B, Sen M, O’Toole L, Dyker K, Al Booz H, Moleron R, Brennan S, Aynsley E, Chan A, Srinivasan D, Buter J, Dunn J (2018) Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. Ann Oncol 29(suppl_8). https://​doi.​org/​10.​1093/​annonc/​mdy424.​046 CrossRef
19.
Zurück zum Zitat National Institutes of Health (2018) Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer National Institutes of Health (2018) Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer
20.
Zurück zum Zitat Haughey BH, Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, Milov S, Lewis JS Jr, Krishna M (2011) Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 33(12):1683–1694PubMedCrossRef Haughey BH, Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, Milov S, Lewis JS Jr, Krishna M (2011) Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 33(12):1683–1694PubMedCrossRef
21.
Zurück zum Zitat Sinha P, Lewis JS Jr, Piccirillo JF, Kallogjeri D, Haughey BH (2012) Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 118(14):3519–3530PubMedCrossRef Sinha P, Lewis JS Jr, Piccirillo JF, Kallogjeri D, Haughey BH (2012) Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 118(14):3519–3530PubMedCrossRef
22.
Zurück zum Zitat Mattheis S, Hasskamp P, Holtmann L, Schäfer C, Geisthoff U, Dominas N, Lang S (2017) Flex robotic system in transoral robotic surgery: the first 40 patients. Head Neck 39(3):471–475PubMedCrossRef Mattheis S, Hasskamp P, Holtmann L, Schäfer C, Geisthoff U, Dominas N, Lang S (2017) Flex robotic system in transoral robotic surgery: the first 40 patients. Head Neck 39(3):471–475PubMedCrossRef
23.
Zurück zum Zitat Kwok P, Gleich O, Hübner G, Strutz J (2010) Prognostic importance of „clear versus revised margins“ in oral and pharyngeal cancer. Head Neck 32(11):1479–1484PubMedCrossRef Kwok P, Gleich O, Hübner G, Strutz J (2010) Prognostic importance of „clear versus revised margins“ in oral and pharyngeal cancer. Head Neck 32(11):1479–1484PubMedCrossRef
24.
Zurück zum Zitat Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94:2511–2516PubMedCrossRef Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94:2511–2516PubMedCrossRef
25.
Zurück zum Zitat Meier JD, Oliver DA, Varvares MA (2005) Surgical margin determination in head and neck oncology: current clinical practice. The results of an international american head and neck society member survey. Head Neck 27:952–958PubMedCrossRef Meier JD, Oliver DA, Varvares MA (2005) Surgical margin determination in head and neck oncology: current clinical practice. The results of an international american head and neck society member survey. Head Neck 27:952–958PubMedCrossRef
26.
Zurück zum Zitat Slootweg PJ, Hordijk GJ, Schade Y, van Es RJJ, Koole R (2002) Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol 38:500–503PubMedCrossRef Slootweg PJ, Hordijk GJ, Schade Y, van Es RJJ, Koole R (2002) Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol 38:500–503PubMedCrossRef
27.
Zurück zum Zitat Wittekind C (2006) Residualtumorklassifikation in der Onkologie. Anwendungen und Probleme. Onkologe 12:803–814CrossRef Wittekind C (2006) Residualtumorklassifikation in der Onkologie. Anwendungen und Probleme. Onkologe 12:803–814CrossRef
28.
Zurück zum Zitat Wittekind C, Meyer HJ (2010) TNM-Klassifikation maligner Tumoren, 7. Aufl. Wiley-Blackwell, Weinheim Wittekind C, Meyer HJ (2010) TNM-Klassifikation maligner Tumoren, 7. Aufl. Wiley-Blackwell, Weinheim
30.
Zurück zum Zitat Laccourreye O, Malinvaud D, Garcia D, Ménard M, Hans S, Cauchois R, Bonfils P (2015) Postoperative hemorrhage after transoral oropharyngectomy for cancer of the lateral oropharynx. Ann Otol Rhinol Laryngol 124(5):361–367PubMedCrossRef Laccourreye O, Malinvaud D, Garcia D, Ménard M, Hans S, Cauchois R, Bonfils P (2015) Postoperative hemorrhage after transoral oropharyngectomy for cancer of the lateral oropharynx. Ann Otol Rhinol Laryngol 124(5):361–367PubMedCrossRef
31.
Zurück zum Zitat Salassa JR, Hinni ML, Grant DG, Hayden RE (2008) Postoperative bleeding in transoral laser microsurgery for upper aerodigestive tract tumors. Otolaryngol Head Neck Surg 139(3):453–459PubMedCrossRef Salassa JR, Hinni ML, Grant DG, Hayden RE (2008) Postoperative bleeding in transoral laser microsurgery for upper aerodigestive tract tumors. Otolaryngol Head Neck Surg 139(3):453–459PubMedCrossRef
32.
Zurück zum Zitat Pollei TR, Hinni ML, Moore EJ, Hayden RE, Olsen KD, Casler JD, Walter LC (2013) Analysis of postoperative bleeding and risk factors in transoral surgery of the oropharynx. Jama Otolaryngol Head Neck Surg 139(11):1212–1218PubMedCrossRef Pollei TR, Hinni ML, Moore EJ, Hayden RE, Olsen KD, Casler JD, Walter LC (2013) Analysis of postoperative bleeding and risk factors in transoral surgery of the oropharynx. Jama Otolaryngol Head Neck Surg 139(11):1212–1218PubMedCrossRef
33.
Zurück zum Zitat Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134:536–538PubMedCrossRef Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134:536–538PubMedCrossRef
34.
Zurück zum Zitat Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, Nutting C, Powell N, Al-Booz H, Robinson M, Junor E, Rizwanullah M, von Zeidler SV, Wieshmann H, Hulme C, Smith AF, Hall P, Dunn J, PET-NECK Trial Management Group (2016) PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 374(15):1444–1454PubMedCrossRef Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, Nutting C, Powell N, Al-Booz H, Robinson M, Junor E, Rizwanullah M, von Zeidler SV, Wieshmann H, Hulme C, Smith AF, Hall P, Dunn J, PET-NECK Trial Management Group (2016) PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 374(15):1444–1454PubMedCrossRef
35.
Zurück zum Zitat Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantù G (2003) Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21(2):327–333PubMedCrossRef Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, Quattrone P, Valagussa P, Bonadonna G, Molinari R, Cantù G (2003) Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21(2):327–333PubMedCrossRef
36.
Zurück zum Zitat Inhestern J, Schmalenberg H, Dietz A, Rotter N, Maschmeyer G, Jungehülsing M, Grosse-Thie C, Kuhnt T, Görner M, Sudhoff H, Wittekindt C, Guntinas-Lichius O (2017) A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5‑fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Ann Oncol 28(8):1917–1922PubMedCrossRef Inhestern J, Schmalenberg H, Dietz A, Rotter N, Maschmeyer G, Jungehülsing M, Grosse-Thie C, Kuhnt T, Görner M, Sudhoff H, Wittekindt C, Guntinas-Lichius O (2017) A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5‑fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Ann Oncol 28(8):1917–1922PubMedCrossRef
37.
Zurück zum Zitat Wichmann G, Krüger A, Boehm A, Kolb M, Hofer M, Fischer M, Müller S, Purz S, Stumpp P, Sabri O, Dietz A, Kluge R (2017) Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT. Eur J Cancer 72:144–155PubMedCrossRef Wichmann G, Krüger A, Boehm A, Kolb M, Hofer M, Fischer M, Müller S, Purz S, Stumpp P, Sabri O, Dietz A, Kluge R (2017) Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT. Eur J Cancer 72:144–155PubMedCrossRef
38.
Zurück zum Zitat Seiwert TY, Clement PM, Cupissol D, Del Campo J, de Mont-Serrat H, Thurm HC, Blackman AS, Cohen EE (2010) BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. J Clin Oncol 28:15s (suppl; abstr 5501)CrossRef Seiwert TY, Clement PM, Cupissol D, Del Campo J, de Mont-Serrat H, Thurm HC, Blackman AS, Cohen EE (2010) BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. J Clin Oncol 28:15s (suppl; abstr 5501)CrossRef
39.
Zurück zum Zitat Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK (2004) Postoperative concurrent radiotherapy and chemotherapy for high risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944PubMedCrossRef Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK (2004) Postoperative concurrent radiotherapy and chemotherapy for high risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944PubMedCrossRef
40.
Zurück zum Zitat Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84(5):1198–1205PubMedPubMedCentralCrossRef Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84(5):1198–1205PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabecke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952PubMedCrossRef Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabecke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952PubMedCrossRef
42.
Zurück zum Zitat Fietkau R, Lautenschläger C, Sauer R, Dunst J, Becker A, Baumann M, Wendt T, Grüschow K, Hess C, Budach V, Iro H (2006) Postoperative concurrent radiochemotherapy versus radiotherapy in high risk SCCA of head and neck: results of the German phase III trial ARO 96-3. J Clin Oncol 24(18_suppl):5507 (ASCO Annual Meeting Proceedings Part I) Fietkau R, Lautenschläger C, Sauer R, Dunst J, Becker A, Baumann M, Wendt T, Grüschow K, Hess C, Budach V, Iro H (2006) Postoperative concurrent radiochemotherapy versus radiotherapy in high risk SCCA of head and neck: results of the German phase III trial ARO 96-3. J Clin Oncol 24(18_suppl):5507 (ASCO Annual Meeting Proceedings Part I)
43.
Zurück zum Zitat Pignon JP, Le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NH): an update on 93 randomised trials and 17346 patients. Radiother Oncol 92:4–14PubMedCrossRef Pignon JP, Le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NH): an update on 93 randomised trials and 17346 patients. Radiother Oncol 92:4–14PubMedCrossRef
44.
Zurück zum Zitat Budach W, Hehr T, Budach V, Belka C, Dietz K (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28PubMedPubMedCentralCrossRef Budach W, Hehr T, Budach V, Belka C, Dietz K (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, Soulieres D, Trotti A, Avizonis V, Ridge JA, Harris J, Le QT, Gillison M (2014) Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32(30):3365–3373PubMedPubMedCentralCrossRef Fakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, Soulieres D, Trotti A, Avizonis V, Ridge JA, Harris J, Le QT, Gillison M (2014) Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 32(30):3365–3373PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Goodwin WJ Jr. (2000) Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 110(3 Pt 2 Suppl 93):1–18PubMedCrossRef Goodwin WJ Jr. (2000) Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 110(3 Pt 2 Suppl 93):1–18PubMedCrossRef
48.
Zurück zum Zitat Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127PubMedCrossRef Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127PubMedCrossRef
49.
Zurück zum Zitat Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867PubMedPubMedCentralCrossRef Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Soulières D, Cohen EEW, Le Tourneau C, Didis J, Licitra L, Ahn M, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Harrington KJ (2018) Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous carcinoma. Abstract AACR 2018CrossRef Soulières D, Cohen EEW, Le Tourneau C, Didis J, Licitra L, Ahn M, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby R, Harrington KJ (2018) Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous carcinoma. Abstract AACR 2018CrossRef
51.
Zurück zum Zitat Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G Jr, Psyrri A, Baste Rotllan N, Neupane PC, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Roy A, Cheng J, Jin F, Rischin D (2018) KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) LBA8_PR. Ann Oncol 29:8CrossRef Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G Jr, Psyrri A, Baste Rotllan N, Neupane PC, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Roy A, Cheng J, Jin F, Rischin D (2018) KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) LBA8_PR. Ann Oncol 29:8CrossRef
52.
Zurück zum Zitat SIKO (2017) Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen (Stand Januar 2017. Impfempfehlungen E1: 1–30.) SIKO (2017) Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen (Stand Januar 2017. Impfempfehlungen E1: 1–30.)
53.
Zurück zum Zitat Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsagué X (2012) Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 12:30PubMedPubMedCentralCrossRef Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsagué X (2012) Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 12:30PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat D’Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C (2014) Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS ONE 9(1):e86023PubMedPubMedCentralCrossRef D’Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C (2014) Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS ONE 9(1):e86023PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat D’Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR (2014) Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol 32(23):2408–2415PubMedPubMedCentralCrossRef D’Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, Gerber J, Gillison ML, Posner MR (2014) Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol 32(23):2408–2415PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjønneland A, Overvad K, Quirós JR, González CA, Sánchez MJ, Larrañaga N, Navarro C, Barricarte A, Travis RC, Khaw KT, Wareham N, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, Panico S, Masala G, Grioni S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Laurell G, Hallmans G, Manjer J, Ekström J, Skeie G, Lund E, Weiderpass E, Ferrari P, Byrnes G, Romieu I, Riboli E, Hildesheim A, Boeing H, Pawlita M, Brennan P (2013) Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. Clin Oncol 31(21):2708–2715CrossRef Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D, Tjønneland A, Overvad K, Quirós JR, González CA, Sánchez MJ, Larrañaga N, Navarro C, Barricarte A, Travis RC, Khaw KT, Wareham N, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, Panico S, Masala G, Grioni S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Laurell G, Hallmans G, Manjer J, Ekström J, Skeie G, Lund E, Weiderpass E, Ferrari P, Byrnes G, Romieu I, Riboli E, Hildesheim A, Boeing H, Pawlita M, Brennan P (2013) Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. Clin Oncol 31(21):2708–2715CrossRef
57.
Zurück zum Zitat Holzinger D, Wichmann G, Baboci L, Michel A, Höfler D, Wiesenfarth M, Schroeder L, Boscolo-Rizzo P, Herold-Mende C, Dyckhoff G, Boehm A, Del Mistro A, Bosch FX, Dietz A, Pawlita M, Waterboer T (2017) Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer 140(12):2748–2757PubMedCrossRef Holzinger D, Wichmann G, Baboci L, Michel A, Höfler D, Wiesenfarth M, Schroeder L, Boscolo-Rizzo P, Herold-Mende C, Dyckhoff G, Boehm A, Del Mistro A, Bosch FX, Dietz A, Pawlita M, Waterboer T (2017) Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer 140(12):2748–2757PubMedCrossRef
58.
Zurück zum Zitat O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W (2013) Deintensification candidate subgroups in human papillomavirus–related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31(5):543–550PubMedCrossRef O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W (2013) Deintensification candidate subgroups in human papillomavirus–related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31(5):543–550PubMedCrossRef
59.
Zurück zum Zitat Weinstein GS, O’Malley BW Jr, Magnuson JS, Carroll WR, Olsen KD, Daio L, Moore EJ, Holsinger FC (2012) Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope 122(8):1701–1707PubMedCrossRef Weinstein GS, O’Malley BW Jr, Magnuson JS, Carroll WR, Olsen KD, Daio L, Moore EJ, Holsinger FC (2012) Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope 122(8):1701–1707PubMedCrossRef
60.
Zurück zum Zitat Crespo AN, Chone CT, Gripp FM, Spina AL, Altemani A (2006) Role of margin status in recurrence after CO2 laser endoscopic resection of early glottic cancer. Acta Otolaryngol 126:306–310PubMedCrossRef Crespo AN, Chone CT, Gripp FM, Spina AL, Altemani A (2006) Role of margin status in recurrence after CO2 laser endoscopic resection of early glottic cancer. Acta Otolaryngol 126:306–310PubMedCrossRef
61.
Zurück zum Zitat Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, Marandas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B, French Groupe d’Etude des Tumeurs de la Tête et du Cou (GETTEC) (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 83(12):1594–1598PubMedPubMedCentralCrossRef Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, Marandas P, Coche-Dequeant B, Stromboni-Luboinski M, Sancho-Garnier H, Luboinski B, French Groupe d’Etude des Tumeurs de la Tête et du Cou (GETTEC) (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 83(12):1594–1598PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY (2013) Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31(6):744–751PubMedCrossRef Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZY (2013) Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol 31(6):744–751PubMedCrossRef
Metadaten
Titel
Behandlungsstrategien beim Oropharynxkarzinom
verfasst von
Prof. Dr. Andreas Dietz
Publikationsdatum
28.01.2019
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 3/2019
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-018-0514-9

Weitere Artikel der Ausgabe 3/2019

Die Onkologie 3/2019 Zur Ausgabe

Passend zum Thema

ANZEIGE

Pikosekundenlaser stimuliert Reparaturmechanismen der Haut

Eine beim ASLMS 2024 vorgestellte Studie mit einem 3D-Hautmodell zeigt, dass eine Pikosekunden-Laserbehandlung über den Mechanismus des „laser-induced optical breakdown“ (LIOB) die Regenerationsmechanismen der Haut stimuliert. Diese positiven Effekte von LIOB konnten durch eine Nachbehandlung mit Dexpanthenol-haltiger Salbe unterstützt und beschleunigt werden.

ANZEIGE

Wund- und Heilsalbe mit Dexpanthenol zur Tattoo-Nachsorge geeignet

Eine klinische Studie unterstreicht die Eignung der Dexpanthenol-haltigen Bepanthen® Wund- und Heilsalbe für die Nachsorge frisch tätowierter Hautstellen [1]. Dass die Gabe von Pantothenat (aktiver Metabolit von Dexpanthenol) die Aufnahme von Tattoo-Farbe in die Makrophagen steigert und so die Beständigkeit von Tätowierungen erhöhen kann, zeigte eine In-vitro-Studie [2].

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.

Bayer Vital GmbH

Passend zum Thema

ANZEIGE

Pneumokokken-Impfschutz bei den Kleinsten oft unvollständig

Rund einem Viertel aller Kinder bis zum 2. Lebensjahr fehlt ein ausreichender Pneumokokken-Impfschutz. Doch warum ist eine frühzeitige Säuglingsimpfung wichtig?

ANZEIGE

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

ANZEIGE

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

MSD Sharp & Dohme GmbH